Opinionated Science Episode 6: COVID-19: Repurposing Drugs, Hydroxychloroquine and Clinical Trials

Podcast

Published: June 5, 2020

Opinionated Science Episode 6: COVID-19: Repurposing Drugs, Hydroxychloroquine and Clinical Trials content piece image

Opinionated Science is Technology Networks’ homemade podcast, where our team of scientists-turned-journalists cut out the chewy jargon and serve up slices of the most fascinating stories from the world of science. Expect a new Opinionated Science every other Friday.

In this episode, the Technology Networks team discusses drug treatments to combat SARS-CoV-2. These drugs, like the anti-malarial hydroxychloroquine, have often been repurposed for the task, and evidence for their efficacy remains patchy. Why do researchers turn to these medications and how will the field of drug development be changed by the COVID-19 pandemic?

Read more from this podcast:

Hydroxychloroquine Revived by WHO

How modeling can support drug development

Covid-19 brings drug development to a halt

Tackling Covid-19: ongoing drug development efforts

Flooded by the torrent: the COVID-19 drug pipeline

Global impact on clinical trials

What is a preprint?

Exploring the drug development process

Keep up to date with COVID-19 vaccine development

Updates:

Hydroxychloroquine arm stopped in RECOVERY Trial

Listen to more Technology Networks podcasts here.

Subscribe to Opinionated Science at your favorite podcast platform:

Listen here on Spotify.

Listen here on Apple Podcasts.

Meet the Authors

Laura Elizabeth Lansdowne

Managing Editor

Laura Lansdowne is the managing editor at Technology Networks, she holds a first-class honors degree in biology. Before her move into scientific publishing, Laura worked at the Wellcome Sanger Institute and GW Pharma.

Ruairi J Mackenzie

RJ is a freelance science writer based in Glasgow. He covers biological and biomedical science, with a focus on the complexities and curiosities of the brain and emerging AI technologies. RJ was a science writer at Technology Networks for six years. RJ has a Master’s degree in Clinical Neurosciences from the University of Cambridge.

Tiffany Quinn

After obtaining a bachelor in neuroscience from the University of Leeds, Tiffany joined Technology Networks to pursue a career in science communication as a custom content producer and manager. She has helped grow the company’s custom content services through creating high-quality and engaging content for client’s target audiences. Tiffany left TN in 2023 to pursue other career goals.

“This Podcast Will Kill You” Hosts Talk Successful Science Communication, Overcoming Failure and Quarantinis

A young baby curled up asleep in the hands of a man and a woman.

Article

Mycotoxin Exposure and Early Life Gut Microbiome Development in Nigerian Neonates and Infants

A microplate containing tumoroids, zoomed in image of the individual wells and further magnification of the GEP-NENs tumoroid

Article

Cell Science

Cell Science

Opinionated Science Episode 6: COVID-19: Repurposing Drugs, Hydroxychloroquine and Clinical Trials

“This Podcast Will Kill You” Hosts Talk Successful Science Communication, Overcoming Failure and Quarantinis

Mycotoxin Exposure and Early Life Gut Microbiome Development in Nigerian Neonates and Infants

Unveiling Novel Therapeutic Targets for Neuroendocrine Cancers: A Precision Medicine Breakthrough